(Q34283153)

1 August 2017

1 reference

title

Olanzapine: another psychotropic? (English)

1 reference

1 August 2017

M P Davis

1

1 reference

1 August 2017

E D Dickerson

series ordinal

2

1 reference

1 August 2017

publication date

1 March 2001

1 reference

American Journal of Hospice and Palliative Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

18

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

129-132

1 reference

Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Olanzapine in treatment-resistant bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Neuroleptic malignant syndrome associated with olanzapine therapy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Olanzapine. A pharmacoeconomic review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

Efficacy and Tolerability of Olanzapine in Elderly Patients with Psychotic Disorders: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800212

10.1177/104990910101800212

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference